{"schema_version":"1","generated_at":"2026-10-29T13:15:42.017Z","data_as_of":"2026-10-26","url":"https://www.findmykol.com/kol/tufia-haddad","json_url":"https://www.findmykol.com/kol/tufia-haddad/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"tufia-haddad","name":"Tufia Haddad","credential":"MD","title":"Associate professor of oncology, Mayo Clinic College of Medicine and Science","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Breast","therapeutic_areas":["Breast"],"institution":"Mayo Clinic Rochester","institution_url":"https://www.findmykol.com/institution/mayo-clinic","city":"Rochester","state":"MN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1215062989","orcid":"0000-0001-8226-3581","openalex":"A5031366322"},"summary":"Tufia Haddad is Associate professor of oncology, Mayo Clinic College of Medicine and Science at Mayo Clinic Rochester. OpenAlex indexes 279 publications with 6,047 citations (h-index 38); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.","overview":{"text":"Tufia Haddad, MD, is Associate professor of oncology, Mayo Clinic College of Medicine and Science at Mayo Clinic Rochester. The public record shows 279 publications with 6,047 citations (h-index 38), centered on Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, Telemedicine and Telehealth Implementation. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 5 companies, 2 NIH-funded awards (2017–2026).","bullets":["Most recent indexed publication: 2026 · BMJ open","Top research focus: Breast Cancer Treatment Studies","8 registered trials on ClinicalTrials.gov","Open Payments reporting from 5 companies"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":6,"topics":2,"strength":20},{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Glioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Astrocytoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Oligodendroglioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Breast Cancer Treatment Studies","Advanced Breast Cancer Therapies","Telemedicine and Telehealth Implementation","Estrogen and related hormone effects","Cancer Treatment and Pharmacology"],"works_with":{"total":8,"shown":3,"withheld":5,"rows":[{"name":"Mayo Clinic","trials":6,"payments":0,"mentions":6},{"name":"AstraZeneca Pharmaceuticals LP","trials":0,"payments":4,"mentions":4},{"name":"Puma Biotechnology, Inc.","trials":0,"payments":4,"mentions":4}]}},"scholarship":{"works_count":279,"cited_by_count":6047,"h_index":38,"i10_index":92,"pubmed_count":19,"latest_activity_year":2026,"source":"works"},"trials":{"count":8,"shown":3,"withheld":5,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT06625047","title":"Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy","phase":"PHASE4","status":"COMPLETED","role":"Investigator","sponsor":"Mayo Clinic","source_url":"https://clinicaltrials.gov/study/NCT06625047","trial_url":"https://www.findmykol.com/trial/NCT06625047"},{"nct":"NCT05879926","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","phase":"PHASE3","status":"RECRUITING","role":"Investigator","sponsor":"NRG Oncology","source_url":"https://clinicaltrials.gov/study/NCT05879926","trial_url":"https://www.findmykol.com/trial/NCT05879926"},{"nct":"NCT05744180","title":"A Study of Workflow-Integrated Artificial Intelligence for RPM Enrollment","phase":"NA","status":"COMPLETED","role":"Investigator","sponsor":"Mayo Clinic","source_url":"https://clinicaltrials.gov/study/NCT05744180","trial_url":"https://www.findmykol.com/trial/NCT05744180"}],"source":"trials"},"payments":{"company_count":5,"program_years":{"first":2021,"last":2025},"rows_total":7,"shown":3,"withheld":4,"rows":[{"payer":"PUMA BIOTECHNOLOGY, INC.","program_year":2025,"amount_usd":2613,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215062989"},{"payer":"TAIHO ONCOLOGY, INC.","program_year":2025,"amount_usd":193.87,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215062989"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":122.36,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215062989"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1215062989","source":"payments"},"prescribing":{"data_year":2024,"areas_total":4,"areas_shown":3,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":50.2,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"administered","share_pct":50.2,"drugs":[{"name":"Palonosetron hcl","share_pct":54},{"name":"Ondansetron hydrochloride","share_pct":46}],"max_beneficiaries":15}]},{"area":"Sensory organs","share_pct":41.9,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"administered","share_pct":41.9,"drugs":[{"name":"Dexamethasone sodium phosphate","share_pct":100}],"max_beneficiaries":21}]},{"area":"Cancer & immunology","share_pct":5.1,"classes_total":1,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":5.1,"drugs":[{"name":"Letrozole","share_pct":100}],"max_beneficiaries":11}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":2,"fiscal_years":{"first":2017,"last":2026},"rows_total":6,"shown":3,"withheld":3,"rows":[{"project":"UG3CA315308","title":"Evaluation of a novel remote patient monitoring program for cancer patients initiating cancer-directed therapy: The SHIELD (Smart Health Integration for Early Life-saving Detection)","fiscal_year":2026,"amount_usd":569282,"organization":"MAYO CLINIC ROCHESTER","source_url":"https://reporter.nih.gov/quickSearch/UG3CA315308"},{"project":"R01CA214893","title":"Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer","fiscal_year":2021,"amount_usd":315236,"organization":"MAYO CLINIC ROCHESTER","source_url":"https://reporter.nih.gov/quickSearch/R01CA214893"},{"project":"R01CA214893","title":"Targeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast Cancer","fiscal_year":2020,"amount_usd":324060,"organization":"MAYO CLINIC ROCHESTER","source_url":"https://reporter.nih.gov/quickSearch/R01CA214893"}],"source":"grants"},"congress":{"count":72,"years":{"first":2010,"last":2026},"societies":["AACR","ASCO","ASH","ASTRO","ESMO","SABCS"],"shown":3,"withheld":69,"rows":[{"title":"Abstract 2744: Automating clinical and pathological staging for breast cancer patients.","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-2744","source_url":"https://doi.org/10.1158/1538-7445.am2026-2744","status":"verified"},{"title":"Abstract 7599: HOUSES as a screening tool for cancer screening: Patient-level housing-based socioeconomic status and breast and cervical cancer screening adherence.","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-7599","source_url":"https://doi.org/10.1158/1538-7445.am2026-7599","status":"verified"},{"title":"A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2– breast cancer and Oncotype recurrence score ≤ 25 (OFSET): NRG-BR009.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps650","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps650","status":"verified"}],"source":"congress"},"publications":{"total":19,"shown":5,"withheld":14,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"WeCare intervention to improve breast cancer screening and research preparedness in rural and low-socioeconomic women: study protocol for a community-engaged feasibility trial.","year":2026,"journal":"BMJ open","types":["Journal Article","Clinical Trial Protocol"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42225362/","status":"verified"},{"title":"Barriers, Facilitators, and Attitudes Toward Telemedicine Adoption in Oncology: A Qualitative Study of Patients From Low-Broadband Areas.","year":2026,"journal":"JCO oncology practice","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41861270/","status":"verified"},{"title":"Telehealth Utilization in Neuro-Oncology: Commentary on a Single Institution Experience After the COVID-19 Pandemic.","year":2024,"journal":"Current oncology reports","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/39083169/","status":"verified"},{"title":"Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial.","year":2024,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Clinical Trial","Journal Article","Multicenter Study"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/38752717/","status":"verified"},{"title":"Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.","year":2024,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Clinical Trial, Phase III","Journal Article","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/38109213/","status":"verified"}],"most_cited":{"total":279,"shown":5,"withheld":274,"rows":[{"title":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer","year":2020,"cited_by_count":709,"type":"article","source_url":"https://doi.org/10.1001/jamaoncol.2019.6650"},{"title":"Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer","year":2016,"cited_by_count":555,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1513749"},{"title":"Adaptive Randomization of Neratinib in Early Breast Cancer","year":2016,"cited_by_count":455,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1513750"},{"title":"Chemotherapy-induced thrombosis","year":2006,"cited_by_count":359,"type":"article","source_url":"https://doi.org/10.1016/j.thromres.2005.10.015"},{"title":"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)","year":2021,"cited_by_count":235,"type":"article","source_url":"https://doi.org/10.1200/jco.21.02554"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Matthew Philip Goetz","coauthored_works":71},{"name":"Kathryn J. Ruddy","coauthored_works":45},{"name":"Karthik V. Giridhar","coauthored_works":42}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/tufia-haddad-md","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":3,"shown":3,"rows":[{"value":"Board certified in Medical Oncology, American Board of Internal Medicine, 2008","source_url":"https://www.mayo.edu/research/faculty/haddad-tufia-c-m-d/bio-10029575","status":"verified","collected_at":"2026-10-28"},{"value":"MD, Creighton University School of Medicine, 2001","source_url":"https://www.mayo.edu/research/faculty/haddad-tufia-c-m-d/bio-10029575","status":"provisional","collected_at":"2026-10-28"},{"value":"BS in Biology, Marquette University, 1995","source_url":"https://www.mayo.edu/research/faculty/haddad-tufia-c-m-d/bio-10029575","status":"provisional","collected_at":"2026-10-28"}]},"roles":{"total":3,"shown":3,"rows":[{"value":"Enterprise co-leader of Platform and Digital Innovation, Mayo Clinic Cancer Center","source_url":"https://alumniassociation.mayo.edu/colleague-notes/tufia-haddad-m-d-division-of-medical-oncology-mayo-clinic-in-rochester/","status":"verified","collected_at":"2026-10-28"},{"value":"Chair of Practice Innovation and Platform, Mayo Clinic Comprehensive Cancer Center","source_url":"https://www.mayo.edu/research/faculty/haddad-tufia-c-m-d/bio-10029575","status":"verified","collected_at":"2026-10-28"},{"value":"Medical Director of Care at Home, Center for Digital Health","source_url":"https://www.mayo.edu/research/faculty/haddad-tufia-c-m-d/bio-10029575","status":"verified","collected_at":"2026-10-28"}]},"awards":{"total":1,"shown":1,"rows":[{"value":"Minnesota Monthly Top Doctor (2015-2017)","source_url":"https://www.mayo.edu/research/faculty/haddad-tufia-c-m-d/bio-10029575","status":"verified","collected_at":"2026-10-28"}]}},"similar":[{"name":"Edward Loftus","slug":"edward-loftus","institution":"Mayo Clinic Rochester","specialty":"Gastroenterology","url":"https://www.findmykol.com/kol/edward-loftus","json_url":"https://www.findmykol.com/kol/edward-loftus/profile.json"},{"name":"Martha Lacy","slug":"martha-lacy","institution":"Mayo Clinic Rochester","specialty":"Hematology","url":"https://www.findmykol.com/kol/martha-lacy","json_url":"https://www.findmykol.com/kol/martha-lacy/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Eric Winer","slug":"eric-winer","institution":"Yale School of Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/eric-winer","json_url":"https://www.findmykol.com/kol/eric-winer/profile.json"},{"name":"Norman Wolmark","slug":"norman-wolmark","institution":"University of Pittsburgh","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/norman-wolmark","json_url":"https://www.findmykol.com/kol/norman-wolmark/profile.json"},{"name":"Hope Rugo","slug":"hope-rugo","institution":"City of Hope","specialty":"Hematology","url":"https://www.findmykol.com/kol/hope-rugo","json_url":"https://www.findmykol.com/kol/hope-rugo/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":5,"payments":4,"funding":3,"congress":69,"publications":14,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-28"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-10-28"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-28"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}